Patterns of Early and Late Recurrence Across Breast Cancer Subtypes in the Canadian Cancer Trials Group MA.32 Trial
Open Access
- 1 July 2026
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (3)
Abstract
Purpose: We describe patterns of early and late recurrence across breast cancer (BC) subtypes (luminal: estrogen and/or progesterone receptor [ER and/or PgR] positive, human epidermal growth factor receptor 2 [HER2] negative); triple negative (TN); HER2+, any ER, PgR in the Canadian Cancer Trials Group MA.32 adjuvant BC trial involving 3,649 patients with high-risk BC. Methods: Post-random assignment annual rates of local and distant recurrences as well as new breast and nonbreast primaries were calculated for each BC subtype and averaged for early (years 0-5) and late (>5 years) events. Results: Patterns of events varied across subtypes and early versus late events. The early versus late annual invasive cancer rates were 3.04 versus 2.31% (late/early 0.76) in luminal, 4.60% and 1.21% (late/early 0.35) in TN and 2.93 versus 1.47% (late/early 0.50) in HER2+. Annual early versus late rates of distant recurrence were 2.33 versus 1.72% (late/early 0.74) in luminal, 3.09 versus 0.2% (late/early 0.28) in TN, and 2.25 versus 0.71% (late/early 0.32) in HER2+. Second primaries were the most frequent late event in patients with TN and HER2+ BC. Conclusion: Risk of late cancer events differed across BC subtypes; distant recurrences were most common in luminal while second primaries were most common in TN and HER2+ BC.Keywords
This publication has 6 references indexed in Scilit:
- Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast CancerClinical Cancer Research, 2025
- Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast CancerJournal of Clinical Oncology, 2023
- Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast CancerJAMA, 2022
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 YearsNew England Journal of Medicine, 2017
- Comparison of Breast Cancer Recurrence and Outcome Patterns Between Patients Treated From 1986 to 1992 and From 2004 to 2008Journal of Clinical Oncology, 2015
- Annual hazard rates of recurrence for breast cancer after primary therapy.Journal of Clinical Oncology, 1996